Enhanced Responses to Fostamatinib As Second-Line Therapy and in Persistent Immune Thrombocytopenia (ITP) Patients
Ralph V. Boccia(Center for Cancer and Blood Disorders), James B. Bussel(Cornell University), Leslie Todd(Tulane University), Anne‐Marie Duliège(Sunesis (United States)), Quentin A. Hill(Leeds Teaching Hospitals NHS Trust), Brian Olender(Rigel (United States)), Waleed Ghanima(Oslo University Hospital), Michael D. Tarantino(Bleeding & Clotting Disorders Institute), Robert P. Numerof(Bayer (United States)), Sandy Tong(Rigel (United States)), Yuliya Kreychman(Rigel (United States)), Michael Boxer(Arizona Oncology), Michelle Sholzberg(St. Michael's Hospital), Nichola Cooper(Imperial College London)
Cited by 3
Related Papers
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
B cell–helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen
|Nature Immunology|2011|724
AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP
|New England Journal of Medicine|2006|530
COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City
|Modern Pathology|2020|478